International Journal of Medicine and Data
International Journal of Medicine and Data. 2022; 6: (6) ; 10.12208/j.ijmd.20220274 .
总浏览量: 488
中山大学附属第八医院 广东深圳
*通讯作者： 杜飞,单位：中山大学附属第八医院 广东深圳；
肝癌是一类严重威胁人类健康的恶性肿瘤，恶性程度较高，起病隐匿，早期症状不典型，确诊时大部分患者已属于中晚期，丧失手术机会。尽管部分患者可进行手术治疗，但术后复发和转移仍严重影响患者的生存期。早期发现和诊断是肝癌临床治疗成功和改善患者预后的关键。肿瘤复发是不可避免的，如何及早发现早期复发和转移，并采取及时干预，显得尤为重要。目前临床上缺乏特异的检查手段进行早期筛查和预后判断。近年来，基于循环肿瘤DNA（circulating tumor DNA ctDNA）的液体活检技术迅速并广受关注。因此，本文探讨循环肿瘤DNA在肝癌诊断和治疗中的应用研究。
Hepatocellular carcinoma (HCC) is a kind of malignant tumor which is a serious threat to human health. It has a high degree of malignancy, insidious onset and atypical early symptoms. Most patients already belong to the middle or late stage and lose the opportunity of surgery when diagnosed. Although some patients can be treated with surgery, postoperative recurrence and metastasis still seriously affect the survival of patients. Early detection and diagnosis is the key to successful clinical treatment and improved prognosis of patients with liver cancer. If tumor recurrence is inevitable, how to detect early recurrence and metastasis, and take timely intervention, is particularly important. At present, there is a lack of specific examination methods for early screening and prognosis. Liquid biopsy techniques based on circulating tumor DNA(ctDNA) have gained rapid and widespread interest in recent years. Therefore, this paper discusses the application of circulating tumor DNA in the diagnosis and treatment of liver cancer.
[1] Zhou M, Wang H, Zeng X , et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2019(10204):394.
[2] Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2018, 68：394-424.
[3] Villanueva A. Hepatocellular Carcinoma[J]. N Engl J Med. 2019, 380(15):1450-1462.
[4] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors - ScienceDirect[J]. Journal of Hepatology, 2008, 48(2):335-352.
[5] Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: natural history and treatment.[J]. Seminars in liver disease, 2006(2):26.
[6] Chen Y C, Chu C M, Yeh C T, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study[J]. Hepatology International, 2007, 1(1):267-273.
[7] Aarthy R, Mani S , Velusami S, et al. Role of Circulat-ing Cell-Free DNA in Cancers[J]. Molecular Diagnosis & Therapy, 2015, 19(6):339-350.
[8] Dawson SJ , Tsui DW, Murtaza M , et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer[J]. N Engl J Med. 2013;368(13):1199-1209.
[9] 刘斌亮,马飞,曾益新.循环肿瘤DNA在乳腺癌内分泌治疗耐药中的应用[J].国际肿瘤学杂志,2017,(10):779-782.
[10] Siravegna G, Mussolin B , Buscarino M, et al . Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients[J]. Nat Med. 2015;21(7):827.
[11] Xu S, Lou F, Wu Y, et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients[J]. Cancer Lett. 2016;370(2):324-331.
[12] Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol. 2004;130(7):417-422.
[13] Hou JL, Zhao W, Lee C, et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries[J]. Clin Gastroenterol Hepatol. 2020;18(2):457-467.
[14] Tzartzeva K, Obi J, Rich NE, et al. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis[J]. Gastroenterology. 2018;154(6):1706-1718.
[15] Kotoh Y, Suehiro Y, Saeki I, et al. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma[J]. Hepatol Commun. 2020;4(3):461-470.
[16] Kisiel JB, Dukek BA, V S R Kanipakam R, et al. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation[J]. Hepatology. 2019;69(3):1180-1192.
[17] Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]. Gut. 2019;68(12):2195-2205.
[18] Cai Z, Chen G, Zeng Y, et al Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma[J]. Clin Cancer Res. 2019;25(17):5284-5294.
[19] Zhang Z , Chen P , Xie H , Cao P . Using circulating tumor DNA as a novel biomarker to screen and diag-nose hepatocellular carcinoma: A systematic review and meta-analysis[J]. Cancer Med. 2020;9(4):1349-1364.
[20] Li F, Qiao CY, Gao S, et al. Circulating Cell-Free DNA of Methylated Insulin-Like Growth Factor-Binding Protein 7 Predicts a Poor Prognosis in Hepatitis B Virus-Associated Hepatocellular Carcinoma After Hepatectomy[J]. Free Radic Res (2018) 52:455–64.
[21] Ren N, Qin LX, Tu H, et al. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma[J]. J Cancer Res Clin Oncol. 2006;132(6):399-407.
[22] Howell J , Atkinson S R , Pinato D J , et al. Mutations in circulating cell-free tumour DNA: Predictors of survival in hepatocellular carcinoma[J]. Liver Cancer International, 2021, 2(2):54-62.
[23] Ye K, Fan Q, Yuan M, et al. Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma[J]. Front Oncol. 2022;12:834992.